JNJ 17203212
SIGMA/J3580 - ≥98% (HPLC)
Synonym: N1-
CAS Number: 821768-06-3
Empirical Formula (Hill Notation): C17H15F6N5O
Molecular Weight: 419.32
Linear Formula: C17H15F6N5O
Product Type: Chemical
| assay | ≥98% (HPLC) |
| color | white to off-white |
| form | powder |
| InChI | 1S/C17H15F6N5O/c18-16(19, |
| InChI key | JFRYYGVYCWYIDQ-UHFFFAOYSA |
| originator | Johnson & Johnson |
| SMILES string | FC(F)(F)c1c(nccc1)N2CCN(C |
| solubility | DMSO: >20 mg/mL |
| storage temp. | −20°C |
| Biochem/physiol Actions: | JNJ 17203212 is a reversible, competitive and potent TRPV1 antagonist that does not inhibit related TRP channels such as TRPV2, TRPV4, or TRPA1. Listed in BJP with IC50= 65 nM. TRPV1 channels are activated by heat, capsaicin and the endocannabinoid anandamide. Interest in TRPV1 antagonists in the transmission and modulation of pain. |
| Biochem/physiol Actions: | JNJ 17203212 is a reversible, competitive and potent TRPV1 antagonist. |
| Features and Benefits: | This compound was developed by Johnson & Johnson . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
| Packaging: | 5, 25 mg in glass bottle |
| Symbol | GHS06 |
| Signal word | Danger |
| Hazard statements | H301-H319 |
| Precautionary statements | P301 + P310-P305 + P351 + P338 |
| Hazard Codes | Xn,Xi |
| Risk Statements | 22-36 |
| Safety Statements | 26 |
| RIDADR | UN 2811 6.1 / PGIII |
| WGK Germany | 3 |
| Purity | ≥98% (HPLC) |
| Storage Temp. | −20°C |
| UNSPSC | 12352200 |

. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, 